Scarica l'app Stockscreener
7.06
8.19%
-0.63
Pre-mercato:
7.09
0.03
+0.42%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$7.69
Aprire:
$6.7
Volume 24 ore:
12.63M
Relative Volume:
2.19
Capitalizzazione di mercato:
$1.84B
Reddito:
$6.28B
Utile/perdita netta:
$700.00M
Rapporto P/E:
2.6224
EPS:
2.6922
Flusso di cassa netto:
$537.00M
1 W Prestazione:
-12.84%
1M Prestazione:
-13.05%
6M Prestazione:
-21.99%
1 anno Prestazione:
-51.97%
Intervallo 1D:
$6.50
$7.28
Intervallo di 1 settimana:
$6.50
$8.43
Portata 52W:
$6.18
$17.23
Organon Co Stock (OGN) Company Profile
Nome
Organon Co
Settore
Industria
Telefono
551-430-6000
Indirizzo
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
7.06 | 2.00B | 6.28B | 700.00M | 537.00M | 2.6922 |
|
LLY
Lilly Eli Co
|
1,038.27 | 908.63B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
244.55 | 580.30B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
227.50 | 390.40B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
204.52 | 317.44B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
161.18 | 305.42B | 54.72B | 14.02B | 15.32B | 7.1855 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Underweight |
| 2025-10-27 | Downgrade | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-09-06 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-11-03 | Downgrade | Goldman | Buy → Neutral |
| 2023-09-21 | Iniziato | Barclays | Overweight |
| 2023-03-16 | Iniziato | Raymond James | Outperform |
| 2022-10-14 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-09-06 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Iniziato | Piper Sandler | Neutral |
| 2021-09-01 | Iniziato | BofA Securities | Buy |
| 2021-07-22 | Iniziato | Citigroup | Buy |
| 2021-06-15 | Iniziato | JP Morgan | Neutral |
| 2021-06-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-06-10 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Organon Co Borsa (OGN) Ultime notizie
Organon & Co. Q4 Earnings Call Highlights - MarketBeat
Organon (NYSE:OGN) Reports Q4 CY2025 In Line With Expectations - The Globe and Mail
Organon & Co To Go Ex-Dividend On February 23rd, 2026 With 0.02 USD Dividend Per Share - 富途牛牛
Organon Earnings Call Balances Stability With Rising Risks - TipRanks
Organon Q3 Net Margin Squeeze Challenges Bullish Earnings Growth Narratives - simplywall.st
Organon Co earnings missed by $0.13, revenue fell short of estimates - Investing.com UK
Organon Shares Slide on Quarterly Loss and Cautious Outlook - AD HOC NEWS
Organon (OGN) Q4 2025 Earnings Call Transcript - The Globe and Mail
Organon & Co. (NYSE:OGN) Announces Quarterly Earnings Results, Misses Estimates By $0.11 EPS - MarketBeat
Organon: Overview of Fourth Quarter Financial Results - Bitget
Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Investors to Inquire about Securities Investigation - ACCESS Newswire
Organon Q4 Earnings ReviewPoor Results Trigger Predictable Sell-Off (NYSE:OGN) - Seeking Alpha
Organon sees FY26 revenue $6.2B, consensus $6.11B - TipRanks
Organon outlines flat $6.2B revenue and $1.9B EBITDA targets for 2026 as cost controls and portfolio shifts take center stage - MSN
Organon reports Q4 adjusted EPS 63c, consensus 73c - TipRanks
Organon Shares Fall After 4Q Earnings Miss Expectations - 富途牛牛
Organon & Co. (NYSE:OGN) Shares Gap Down Following Weak Earnings - MarketBeat
Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
OGN: 2025 results show stable revenue and EBITDA, with 2026 guidance flat amid margin and policy headwinds - TradingView
Organon Q4 2025 slides: Revenue declines accelerate, stock tumbles on earnings miss By Investing.com - Investing.com India
Organon Q4 2025 slides: Revenue declines accelerate, stock tumbles on earnings miss - Investing.com
Organon Co earnings missed by $0.13, revenue fell short of estimates By Investing.com - Investing.com Canada
Earnings call transcript: Organon Q4 2025 reveals EPS miss, stock drops 10.8% - Investing.com
Organon (OGN) Misses Q4 Earnings and Revenue Estimates - Yahoo Finance
Organon falls as women’s health unit drives Q4 miss (OGN:NYSE) - Seeking Alpha
Organon: Q4 Earnings Snapshot - kare11.com
Organon Q4 Adjusted Earnings, Revenue Fall; 2026 Revenue Outlook Issued - 富途牛牛
Earnings snapshot: Organon & Co. misses bottom-line estimates; initiates FY26 outlook - MSN
Organon & Co (NYSE:OGN) Shares Drop on Q4 Earnings Miss and Flat 2026 Outlook - ChartMill
(OGN) Organon Expects 2026 Revenue About $6.22B, vs. FactSet Est of $6.11B - marketscreener.com
Earnings Flash (OGN) Organon Posts Q4 Revenue $1.51B, vs. FactSet Est of $1.54B - marketscreener.com
Organon shares fall over 5% as Q4 earnings miss expectations By Investing.com - Investing.com South Africa
Press Release: Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025 - 富途牛牛
Organon earnings: What to look for from OGN - MSN
Organon Q4 Earnings Preview: Cautious view amid weak year (OGN:NYSE) - Seeking Alpha
Earnings Preview: Organon - Benzinga
Organon & Co. (OGN) Stock Analysis: Exploring A Potential 18.3% Upside In Healthcare - DirectorsTalk Interviews
Organon Earnings: What To Look For From OGN - The Globe and Mail
Organon Q4 Earnings Preview: Revenue Decline Projected Amid Sector VolatilityNews and Statistics - IndexBox
Aug Gainers: Does Organon Co meet Warren Buffetts criteria2025 Momentum Check & Free High Return Stock Watch Alerts - baoquankhu1.vn
Organon & Co. (NYSE:OGN) Stock Price Down 5.2%Here's What Happened - MarketBeat
Down 72% In 3 Years, Can Organon Stock Finally Recover In 2026? - TIKR.com
Organon & Co (OGN.US) will release its earnings report before the market opens on February 12. - 富途牛牛
Contraceptive Pills Market Is Going to Boom | Pfizer Inc • Bayer AG • Organon & Co - openPR.com
FDA expands use of Organon’s contraception implant up to 5 years - MSN
Organon & Co. (NYSE:OGN) Receives Consensus Rating of "Reduce" from Brokerages - MarketBeat
Organon Launches Third Edition of Women's Health Accelerator Program Across Middle East, Turkey & Africa - The Malaysian Reserve
Organon & Co. (OGN) Projected to Post Earnings on Thursday - MarketBeat
Organon Completes Divesture of JADA System to Laborie Medical - MSN
How Organon & Co. (OGN) Affects Rotational Strategy Timing - Stock Traders Daily
Organon & Co: Can This Beaten-Down Women’s Health Specialist Finally Turn a Corner? - AD HOC NEWS
Organon Co Azioni (OGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.94%
0.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):